Home > Back to Publisher > Report Information

Emerging Markets Clinical Development Series Brazil, Russia, India and China (BRIC)

Cutting Edge Information
November 1, 2010
275 Pages - SKU: CIGQ6057013

Abstract Table of Contents Related Reports

Countries covered: India, Russia

The next frontier of global industry expansion makes its home in Brazil, Russia, India and China (BRIC). Imagine the impact of a patient pool that numbers 3 billion — an immediate cure for patient shortages (or recruitment challenges) that plague studies in North America and Western Europe, unparalleled access to untapped patient populations, and new opportunities to meet the growing medical needs of these countries.

Despite vast promise as the next major growth opportunity for life sciences companies, the BRIC countries collectively represent a daunting challenge to new product development strategists and clinical operations teams. Any number of unknowns — unfamiliar regulatory guidelines, intellectual property concerns, time and distance barriers, and tolerance of dishonest business practices — can cause companies to hesitate to invest in these emerging markets or keep them out altogether.

Confidently tap into the potential of the BRIC markets, fulfill protocol, and ultimately, realize significant cost and time savings. Expand your understanding of BRIC, individually and as a whole, using rankings data and best practices to map out a winning clinical strategy:

Eliminate confusion: Weigh the advantages and drawbacks of different countries and examine rankings for 13 cllnical factors to enable strategic decision- making. Gain quick access to relevant demographics and economics information for a comprehensive analysis of the clinical environment.
Master trial management: Learn from top executives’ firsthand experiences — both successes and misfires. Recommendations show your team how to improve CRO selection, management and oversight, and more. Explore 23 in-depth profiles and find one that matches your company’s situation.
Clarify misperceptions: Differences in cultural attitudes and behavior impact trial success. Knowledge and awareness go a long way in cultivating strong and beneficial relationships with local CROs.

Executive Summary: Scoring BRIC; Study Methodology; Participating Companies; Report Layout; Profile Layout; Running Trials in BRIC Countries: Key Recommendations for Success
Brazil: Clinical Environment Overview; Clinical Development Strategy; Clinical Development Profiles
Russia: Clinical Environment Overview; Clinical Development Strategy; Best Practices; Clinical Development Profiles
India: Clinical Environment Overview; Clinical Development Strategy; Clinical Development Profiles
China: Clinical Environment Overview; Clinical Development Strategy; Clinical Development Profiles
CHARTS AND GRAPHICS
Executive Summary: Figure E.1: BRIC Population Compared to US and 5 EU Countries
Scoring BRIC: Figure E.2: Number of Studies Registered by Region; Figure E.3: Number of Studies Registered in BRIC Countries; Figure E.4: Scoring BRIC: Patient Access; Figure E.5: Scoring BRIC: Patient Retention; Figure E.6: Scoring BRIC: Regulatory Environment; Figure E.7: Scoring BRIC: Intellectual Property Laws/Practice; Figure E.8: Scoring BRIC: Cultural Concerns; Figure E.9: Scoring BRIC: Communication/Language; Figure E.10: Scoring BRIC: Trial Technology Infrastructure; Figure E.11: Scoring BRIC: Supply Chain Management; Figure E.12: Scoring BRIC: Available Knowledge Base; Figure E.13: Scoring BRIC: Data Standards; Figure E.14: Scoring BRIC: Investigator Standards; Figure E.15: Scoring BRIC: Site Management Standards; Figure E.16: Average Percent of Budget Saved by Running a Site in BRIC Countries; Figure E.17: Average Percentage of Time Saved by Running a Site in BRIC Countries; Figure E.18: Scoring BRIC: Anticipated Cost
Brazil: Table 1.1: Key Demographic Figures for Brazil, 2010
Clinical Environment Overview: Figure 1.1: Change in Life Expectancy: Brazil (1960-2050); Table 1.2: Top 10 Causes of Death in Brazil, 2002; Figure 1.2: Ethnicities in Brazil (2000 Census); Table 1.3: Key Economic Figures, 2009; Table 1.4: Key Healthcare System Figures, 2005-2009; Figure 1.3: Brazil’s Healthcare Spending as a Percent of GDP (2009); Figure 1.4: Health Spending by Sector (2005); Figure 1.5: Brazil’s Share of the Latin American Pharmaceutical Market (2009); Figure 1.6: Percentage of Budget Saved by Running a Trial in Brazil
Clinical Development Strategy: Figure 1.7: Percentage of Time Saved by Running a Trial in Brazil; Figure 1.8: Assigning Clinical Development Responsibilities for Brazil; Figure 1.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in Brazil; Figure 1.10: Scoring Brazil: Clinical Environment Scores; Figure 1.11: Importance of Factors that Impact Trial Operations for Companies Operating in Brazil; Figure 1.12: Scoring Brazil: Trial Operations Scores; Figure 1.13: Percentage of Total Trial Patients Enrolled in Brazil
Clinical Development Profiles: Figure 1.14: Profile 1: Company Background; Figure 1.15: Profile 1: Experience in BRIC; Figure 1.16: Profile 1: Clinical Strategy in Brazil; Figure 1.17: Profile 1: Scorecard for Brazil; Figure 1.18: Profile 2: Company Background; Figure 1.19: Profile 2: Experience in BRIC; Figure 1.20: Profile 2: Clinical Strategy in Brazil; Figure 1.21: Profile 2: Scorecard for Brazil; Figure 1.22: Profile 3: Company Background; Figure 1.23: Profile 3: Experience in BRIC; Figure 1.24: Profile 3: Clinical Strategy in Brazil; Figure 1.25: Profile 3: Scorecard for Brazil; Figure 1.26: Profile 4: Company Background; Figure 1.27: Profile 4: Experience in BRIC; Figure 1.28: Profile 4: Clinical Strategy in Brazil; Figure 1.29: Profile 4: Scorecard for Brazil; Figure 1.30: Profile 5: Company Background; Figure 1.31: Profile 5: Experience in BRIC; Figure 1.32: Profile 5: Clinical Strategy in Brazil; Figure 1.33: Profile 5: Scorecard for Brazil
Russia
Clinical Environment Overview: Table 2.1: Key Demographic Figures for Russia (2010); Figure 2.1: Change in Life Expectancy: Russia (1960-2050); Table 2.2: Top 10 Causes of Death in Russia (2002); Figure 2.2: Ethnicities in Russia (2002 Census); Table 2.3: Key Economic Figures (2009); Table 2.4: Key Healthcare System Figures (2005-2009); Figure 2.3: Russia’s Healthcare Spending as a Percentage of GDP (2006); Figure 2.4: Russia’s Health Spending by Sector (2005)
Clinical Development Strategy: Figure 2.5: Percent of Total Trial Patients Enrolled in Russia; Figure 2.6: Percentage of Budget Saved by Running Trial in Russia; Figure 2.7: Percentage of Time Saved by Running Trial in Russia; Figure 2.8: Assigning Clinical Development Responsibilities for Russia; Figure 2.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in Russia; Figure 2.10: Scoring Russia: Clinical Environment Scores; Figure 2.11: Importance of Factors that Impact Trial Operations for Companies Operating in Russia; Figure 2.12: Scoring Russia: Trial Operations Scores
Clinical Development Profiles: Figure 2.13: Profile 6: Company Background; Figure 2.14: Profile 6: Experience in BRIC; Figure 2.15: Profile 6: Clinical Strategy in Russia; Figure 2.16: Profile 6: Scorecard for Russia; Figure 2.17: Profile 7: Company Background; Figure 2.18: Profile 7: Experience in BRIC; Figure 2.19: Profile 7: Clinical Strategy in Russia; Figure 2.20: Profile 7: Scorecard for Russia; Figure 2.21: Profile 8: Company Background; Figure 2.22: Profile 8: Experience in BRIC; Figure 2.23: Profile 8: Clinical Strategy in Russia; Figure 2.24: Profile 8: Scorecard for Russia; Figure 2.25: Profile 9: Company Background; Figure 2.26: Profile 9: Experience in BRIC; Figure 2.27: Profile 9: Clinical Strategy in Russia; Figure 2.28: Profile 9: Scorecard for Russia; Figure 2.29: Profile 10: Company Background; Figure 2.30: Profile 10: Experience in BRIC; Figure 2.31: Profile 10: Clinical Strategy in Russia; Figure 2.32: Profile 10: Scorecard for Russia; Figure 2.33: Profile 11: Company Background; Figure 2.34: Profile 11: Experience in BRIC; Figure 2.35: Profile 11: Clinical Strategy in Russia; Figure 2.36: Profile 11: Scorecard for Russia
India
Clinical Environment Overview: Table 3.1: Key Demographic Figures for India (2010); Figure 3.1: Change in Life Expectancy (1960-2050); Table 3.2: Top Ten Causes of Death in India (2002); Figure 3.2: Ethnicities in India (2000 Census); Table 3.3: Key Economic Figures (2009); Figure 3.3: India’s Healthcare Spending as a Percent of GDP (2006); Figure 3.4: Health Spending by Sector (2005); Table 3.4: Key Healthcare System Figures (2005-2009)
Clinical Development Strategy: Figure 3.5: Assigning Clinical Development Responsibilities for India; Figure 3.6: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in India; Figure 3.7: Scoring India: Clinical Environment Scores; Figure 3.8: Importance of Factors that Impact Trial Operations for Companies Operating in India; Figure 3.9: Scoring India: Trial Operations Scores; Figure 3.10: Percent of Total Trial Patients Enrolled in India; Figure 3.11: Percentage of Budget Saved by Running a Trial in India; Figure 3.12: Percentage of Time Saved by Running a Trial in India
Clinical Development Profiles: Figure 3.13: Profile 12: Company Background; Figure 3.14: Profile 12: Experience in BRIC; Figure 3.15: Profile 12: Clinical Strategy in India; Figure 3.16: Profile 12: Scorecard for India; Figure 3.17: Profile 13: Company Background; Figure 3.18: Profile 13: Experience in BRIC; Figure 3.19: Profile 13: Clinical Strategy in India; Figure 3.20: Profile 13: Scorecard for India; Figure 3.21: Profile 14: Company Background; Figure 3.22: Profile 14: Experience in BRIC; Figure 3.23: Profile 14: Clinical Strategy in India; Figure 3.24: Profile 14: Scorecard for India; Figure 3.25: Profile 15: Company Background; Figure 3.26: Profile 15: Experience in BRIC; Figure 3.27: Profile 15: Clinical Strategy in India; Figure 3.28: Profile 15: Scorecard for India; Figure 3.29: Profile 16: Company Background; Figure 3.30: Profile 16: Experience in BRIC; Figure 3.31: Profile 16: Clinical Strategy in India; Figure 3.32: Profile 16: Scorecard for India; Figure 3.33: Profile 17: Company Background; Figure 3.34: Profile 17: Experience in BRIC; Figure 3.35: Profile 17: Clinical Strategy in India; Figure 3.36: Profile 17: Scorecard for India; Figure 3.37: Profile 18: Company Background; Figure 3.38: Profile 18: Experience in BRIC; Figure 3.39: Profile 18: Clinical Strategy in India; Figure 3.40: Profile 18: Scorecard for India
China
Clinical Environment Overview: Table 4.1: Key Demographic Figures for China (2010); Figure 4.1: Change in Life Expectancy: China (1960-2050); Table 4.2: Top 10 Causes of Death in China (2002); Figure 4.2: Ethnicities in China (2000 Census); Table 4.3: China’s Key Economic Figures (2009); Table 4.4: China’s Key Healthcare System Figures, 2005-2009; Figure 4.3: China Healthcare Spending as a Percentage of GDP (2009); Figure 4.4: China’s Health Spending by Sector (2005)
Clinical Development Strategy: Figure 4.5: Percentage of Budget Saved by Running a Trial in China; Figure 4.6: Percentage of Time Saved by Running a Trial in China; Figure 4.7: Assigning Clinical Development Responsibilities for China; Figure 4.8: Scoring China: Clinical Environment Scores; Figure 4.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in China; Figure 4.10: Importance of Factors that Impact Trial Operations for Companies Operating in China; Figure 4.11: Scoring China: Trial Operations Scores; Figure 4.12: Percent of Total Trial Patients Enrolled in China
Clinical Development Profiles: Figure 4.13: Profile 19: Company Background; Figure 4.14: Profile 19: Experience in BRIC; Figure 4.15: Profile 19: Clinical Strategy in China; Figure 4.16: Profile 19: Scorecard for China; Figure 4.17: Profile 20: Company Background; Figure 4.18: Profile 20: Experience in BRIC; Figure 4.19: Profile 20: Clinical Strategy in China; Figure 4.20: Profile 20: Scorecard for China; Figure 4.21: Profile 21: Company Background; Figure 4.22: Profile 21: Experience in BRIC; Figure 4.23: Profile 21: Clinical Strategy in China; Figure 4.24: Profile 21: Scorecard for China; Figure 4.25: Profile 22: Company Background; Figure 4.26: Profile 22: Experience in BRIC; Figure 4.27: Profile 22: Clinical Strategy in China; Figure 4.28: Profile 22: Scorecard for China; Figure 4.29: Profile 23: Company Background; Figure 4.30: Profile 23: Experience in BRIC; Figure 4.31: Profile 23: Clinical Strategy in China; Figure 4.32: Profile 23: Scorecard for China

More Russia Research & Development Reports

Special Report: Opportunities in Emerging Markets—Developing Asia by Decision Resources
Asia boasts 6 of the 20 largest economies in the world: China, Japan, India, Russia, Australia, and Indonesia. The countries of developing Asia are all ...

Clinical Trials Market in Russia by RNCOS
The clinical trials market in Russia is one of the vibrant sectors in the pharmaceutical industry. The country has witnessed huge spending in drug research ...

Pharmaceutical Industry in Russia by Aruvian's R'search
The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs. The earliest incidents of recognition of ...

The Market for Pharmaceuticals in Brazil, Russia, India & China by Espicom Healthcare Intelligence
Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. Market forecasts to 2014 are ...

Russian Pharma Sector Forecast to 2013 by RNCOS
The Russian pharma industry is one of the most prolific sectors in the healthcare industry, showing an unprecedented growth of over 17% to generate revenue ...

See all reports like this >>

More Russia Reports

D&B Country RiskLine Report: The Russian Federation by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

The 2006-2015 Outlook for the Cement Market in Russia by Business Statistics, LLC
The Russian cement market is connected directly with the situation in the construction industry of the country. The world financial crisis affected the construction market ...

Russia This Week by Intellinews
Weekly report on the most significant economic, business, financial markets and political issues and events propelling the Russian ...

Russia This Week by Intellinews
Weekly report on the most significant economic, business, financial markets and political issues and events propelling the Russian ...

Coal - Russia - a snapshot (2010) by Mintel - Snapshots
Coal in Russia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

Emerging Markets Clinical Development Series Brazil, Russia, India and China (BRIC)

Share this report

Other tasks

Research Assistance

Related Markets

Research & Development Reports

Free Alert Me service